Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Enanta management to meet virtually with Roth Capital » 12:55
10/01/20
10/01
12:55
10/01/20
12:55
ENTA

Enanta

$45.36 /

-0.43 (-0.94%)

Webinar with management…

Webinar with management will be held on October 1 at 1 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
ENTA Enanta
$45.36 /

-0.43 (-0.94%)

ENTA Enanta
$45.36 /

-0.43 (-0.94%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ENTA Enanta
$45.36 /

-0.43 (-0.94%)

Conference/Events
Enanta management to meet virtually with Roth Capital » 04:55
10/01/20
10/01
04:55
10/01/20
04:55
ENTA

Enanta

$45.79 /

+1.07 (+2.39%)

Webinar with management…

Webinar with management will be held on October 1 at 1 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
ENTA Enanta
$45.79 /

+1.07 (+2.39%)

ENTA Enanta
$45.79 /

+1.07 (+2.39%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ENTA Enanta
$45.79 /

+1.07 (+2.39%)

Conference/Events
Enanta management to meet virtually with Roth Capital » 12:23
09/24/20
09/24
12:23
09/24/20
12:23
ENTA

Enanta

$42.99 /

-0.35 (-0.81%)

Webinar with management…

Webinar with management will be held on October 1 at 1 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
ENTA Enanta
$42.99 /

-0.35 (-0.81%)

ENTA Enanta
$42.99 /

-0.35 (-0.81%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ENTA Enanta
$42.99 /

-0.35 (-0.81%)

Over a month ago
Hot Stocks
Enanta initiates Phase 1 clinical study of EDP-297 » 07:03
09/14/20
09/14
07:03
09/14/20
07:03
ENTA

Enanta

$46.36 /

+0.14 (+0.30%)

Enanta Pharmaceuticals…

Enanta Pharmaceuticals said in a release, "Enanta Pharmaceuticals announced that it has dosed the first subjects in its Phase 1 clinical trial of EDP-297, a highly potent and targeted follow-on farnesoid X receptor, or FXR, agonist, being developed for the treatment of non-alcoholic steatohepatitis, or NASH. The Phase 1, randomized, double-blind, placebo-controlled, first-in-human study is designed to assess the safety, tolerability, and pharmacokinetics, including the effect of food intake, of orally administered EDP-297 in approximately 74 healthy adult subjects. Two phases are planned: a single ascending dose phase enrolling six cohorts, including a two-part food effect cohort, and a multiple ascending dose phase enrolling three cohorts."

ShowHide Related Items >><<
ENTA Enanta
$46.36 /

+0.14 (+0.30%)

ENTA Enanta
$46.36 /

+0.14 (+0.30%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ENTA Enanta
$46.36 /

+0.14 (+0.30%)

Conference/Events
European Association for the Study of the Liver to hold a conference » 04:55
08/29/20
08/29
04:55
08/29/20
04:55
ABBV

AbbVie

$94.19 /

-0.09 (-0.10%)

, AKRO

Akero Therapeutics

$32.27 /

+0.67 (+2.12%)

, ALBO

Albireo Pharma

$27.15 /

-0.29 (-1.06%)

, AXLA

Axcella Health

$5.07 /

-0.13 (-2.50%)

, AZN

AstraZeneca

$55.66 /

-0.445 (-0.79%)

, BMY

Bristol-Myers

$62.37 /

-0.15 (-0.24%)

, CBAY

CymaBay

$6.14 /

+ (+0.00%)

, DRRX

Durect

$1.81 /

-0.08 (-4.23%)

, ENTA

Enanta

$51.25 /

+1.25 (+2.50%)

, ETNB

89bio

$37.76 /

+0.13 (+0.35%)

, GILD

Gilead

$65.26 /

-0.32 (-0.49%)

, GLMD

Galmed

$5.08 /

+0.02 (+0.40%)

, VKTX

Viking Therapeutics

$6.84 /

-0.6 (-8.06%)

, VBIV

VBI Vaccines

$3.99 /

-0.25 (-5.90%)

, PLRX

Pliant Therapeutics

$25.37 /

+1.01 (+4.15%)

, PFE

Pfizer

$37.90 /

+0.04 (+0.11%)

, NVS

Novartis

$86.64 /

-0.37 (-0.43%)

, NVO

Novo Nordisk

$65.85 /

-0.43 (-0.65%)

, NGM

NGM Biopharmaceuticals

$17.99 /

+0.14 (+0.78%)

, MIRM

Mirum Pharmaceuticals

$24.07 /

+0.47 (+1.99%)

, MDGL

Madrigal Pharmaceuticals

$106.62 /

+0.29 (+0.27%)

, LMNL

Liminal BioSciences

$11.79 /

+0.02 (+0.17%)

, ICPT

Intercept

$49.34 /

+0.62 (+1.27%)

, GNFT

Genfit

$4.92 /

-0.03 (-0.61%)

Digital International…

Digital International Liver Congress 2020 will be held on August 27-29. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

LMNL Liminal BioSciences
$11.79 /

+0.02 (+0.17%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GNFT Genfit
$4.92 /

-0.03 (-0.61%)

GLMD Galmed
$5.08 /

+0.02 (+0.40%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

ENTA Enanta
$51.25 /

+1.25 (+2.50%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
08/20/20 Morgan Stanley
AbbVie price target raised to $108 from $95 at Morgan Stanley
08/19/20 Piper Sandler
AbbVie commercial efforts easier after Gilead CRL, says Piper Sandler
08/19/20 Stifel
Galapagos price target lowered to $155 from $187 at Stifel
AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

08/14/20 Piper Sandler
Piper sees 89bio's topline data beating Akero's in NASH
07/23/20 BTIG
89bio initiated with a Buy at BTIG
07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

08/19/20 H.C. Wainwright
Albireo Pharma price target lowered to $50 from $64 at H.C. Wainwright
07/30/20 Piper Sandler
Albireo Pharma initiated with an Overweight at Piper Sandler
07/16/20 H.C. Wainwright
Albireo price target raised to $64 at H.C. Wainwright after BOLD trial start
06/25/20
Fly Intel: Top five analyst initiations
AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

08/05/20 Piper Sandler
Axcella reported positive hepatic insufficiency data, says Piper Sandler
07/30/20 Piper Sandler
Axcella initiated with an Overweight at Piper Sandler
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 Wedbush
Wedbush bullish on Axcella, initiates with an Outperform
AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CBAY CymaBay
$6.14 /

+ (+0.00%)

08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
08/04/20 H.C. Wainwright
CymaBay price target raised to $13 from $9 at H.C. Wainwright
08/03/20 Cantor Fitzgerald
CymaBay price target raised to $20 from $15 at Cantor Fitzgerald
DRRX Durect
$1.81 /

-0.08 (-4.23%)

07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
07/01/20 H.C. Wainwright
Durect alcoholic hepatitis efficacy could be seen in COVID, says H.C. Wainwright
06/29/20 B. Riley Securities
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ENTA Enanta
$51.25 /

+1.25 (+2.50%)

08/28/20
Fly Intel: Top five analyst initiations
08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
ETNB 89bio
$37.76 /

+0.13 (+0.35%)

07/30/20 Piper Sandler
89bio initiated with an Overweight at Piper Sandler
07/23/20
Fly Intel: Top five analyst initiations
GILD Gilead
$65.26 /

-0.32 (-0.49%)

08/20/20 Truist
Gilead price target lowered to $67 from $74 at Truist
08/19/20 Piper Sandler
Piper Sandler trims Gilead target by $2, keeps Overweight rating
08/19/20 JPMorgan
Gilead CRL for filgotinib 'near worst case scenario,' says JPMorgan
GLMD Galmed
$5.08 /

+0.02 (+0.40%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley Securities
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley Securities
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley Securities
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
06/23/20 Oppenheimer
VBI Vaccines price target raised to $8 from $5 at Oppenheimer
PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

08/11/20 Piper Sandler
Pliant Therapeutics' approach to fibrotic diseases best in industry, says Piper
06/29/20 Needham
Pliant Therapeutics initiated with a Buy at Needham
06/29/20 Cowen
Pliant Therapeutics initiated with an Outperform at Cowen
06/29/20 Citi
Pliant Therapeutics initiated with a Buy at Citi
PFE Pfizer
$37.90 /

+0.04 (+0.11%)

08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
08/25/20 Truist
Forte Biosciences initiated with a Buy at Truist
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/21/20 Mizuho
Pfizer COVID vaccine data 'ok encouraging,' says Mizuho
NVS Novartis
$86.64 /

-0.37 (-0.43%)

08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
08/18/20 Raymond James
Teva could pay damages nearing $1B in DOJ FCA action, says Raymond James
08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

08/12/20 Piper Sandler
NGM Biopharmaceuticals' four pipeline programs underappreciated, says Piper
07/30/20 Piper Sandler
NGM Biopharmaceuticals initiated with an Overweight at Piper Sandler
07/07/20 Chardan
NGM Biopharmaceuticals initiated with a Buy at Chardan
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

07/30/20 Piper Sandler
Madrigal Pharmaceuticals initiated with an Overweight at Piper Sandler
06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley Securities
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
LMNL Liminal BioSciences
$11.79 /

+0.02 (+0.17%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

08/28/20 Piper Sandler
Piper says Intercept data continues to tilt risk/benefit argument raised in CRL
08/10/20 Stifel
Intercept price target raised to $56 from $51 at Stifel
08/10/20 Piper Sandler
Piper Sandler confident in success of Intercept's OCA approval in 2021
GNFT Genfit
$4.92 /

-0.03 (-0.61%)

08/05/20 H.C. Wainwright
Lancet publication 'strong validation' Genfit's NIS4, says H.C. Wainwright
07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

MIRM Mirum Pharmaceuticals
$24.07 /

+0.47 (+1.99%)

MDGL Madrigal Pharmaceuticals
$106.62 /

+0.29 (+0.27%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GLMD Galmed
$5.08 /

+0.02 (+0.40%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

ENTA Enanta
$51.25 /

+1.25 (+2.50%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AXLA Axcella Health
$5.07 /

-0.13 (-2.50%)

ALBO Albireo Pharma
$27.15 /

-0.29 (-1.06%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

  • 18
    Aug
  • 08
    Jul
  • 08
    Jul
  • 03
    Jun
  • 14
    May
  • 22
    Apr
  • 30
    Jan
  • 09
    Jan
  • 11
    Dec
  • 11
    Nov
  • 19
    Sep
VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

VKTX Viking Therapeutics
$6.84 /

-0.6 (-8.06%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PLRX Pliant Therapeutics
$25.37 /

+1.01 (+4.15%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

ICPT Intercept
$49.34 /

+0.62 (+1.27%)

GNFT Genfit
$4.92 /

-0.03 (-0.61%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

ETNB 89bio
$37.76 /

+0.13 (+0.35%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

AKRO Akero Therapeutics
$32.27 /

+0.67 (+2.12%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

VBIV VBI Vaccines
$3.99 /

-0.25 (-5.90%)

PFE Pfizer
$37.90 /

+0.04 (+0.11%)

NVS Novartis
$86.64 /

-0.37 (-0.43%)

NVO Novo Nordisk
$65.85 /

-0.43 (-0.65%)

NGM NGM Biopharmaceuticals
$17.99 /

+0.14 (+0.78%)

GILD Gilead
$65.26 /

-0.32 (-0.49%)

DRRX Durect
$1.81 /

-0.08 (-4.23%)

CBAY CymaBay
$6.14 /

+ (+0.00%)

BMY Bristol-Myers
$62.37 /

-0.15 (-0.24%)

AZN AstraZeneca
$55.66 /

-0.445 (-0.79%)

ABBV AbbVie
$94.19 /

-0.09 (-0.10%)

Initiation
Fly Intel: Top five analyst initiations » 10:12
08/28/20
08/28
10:12
08/28/20
10:12
K

Kellogg

$69.49 /

-0.99 (-1.40%)

, GIS

General Mills

$63.71 /

-1 (-1.55%)

, TRVN

Trevena

$1.73 /

+0.165 (+10.54%)

, BLKB

Blackbaud

$66.07 /

+1.87 (+2.91%)

, ENTA

Enanta

$52.23 /

+2.23 (+4.46%)

, MAXN

Maxeon Solar

$19.11 /

-0.37 (-1.90%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kellogg (K) was initiated with a Buy at Citi, while General Mills (GIS) was initiated with a Neutral. 2. Trevena (TRVN) initiated with an Overweight at Cantor Fitzgerald. 3. Blackbaud (BLKB) initiated with an Overweight at Stephens. 4. Enanta (ENTA) resumed with a Buy at Roth Capital. 5. Maxeon Solar (MAXN) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
TRVN Trevena
$1.73 /

+0.165 (+10.54%)

MAXN Maxeon Solar
$19.11 /

-0.37 (-1.90%)

K Kellogg
$69.49 /

-0.99 (-1.40%)

GIS General Mills
$63.71 /

-1 (-1.55%)

ENTA Enanta
$52.23 /

+2.23 (+4.46%)

BLKB Blackbaud
$66.07 /

+1.87 (+2.91%)

K Kellogg
$69.49 /

-0.99 (-1.40%)

08/28/20 Citi
Kellogg initiated with a Buy at Citi
07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Bernstein
Kellogg's moderating sales growth could weigh on 2H results, says Bernstein
07/30/20 Goldman Sachs
Kellogg downgraded to Neutral from Buy at Goldman Sachs
GIS General Mills
$63.71 /

-1 (-1.55%)

08/28/20 Citi
General Mills initiated with a Neutral at Citi
07/15/20 Guggenheim
General Mills price target raised to $72 from $66 at Guggenheim
07/02/20 BMO Capital
General Mills price target raised to $66 from $63 at BMO Capital
TRVN Trevena
$1.73 /

+0.165 (+10.54%)

08/27/20 Cantor Fitzgerald
Trevena initiated with an Overweight at Cantor Fitzgerald
09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
BLKB Blackbaud
$66.07 /

+1.87 (+2.91%)

08/27/20 Stephens
Blackbaud initiated with an Overweight at Stephens
08/27/20 Stephens
Blackbaud initiated with an Overweight at Stephens
04/20/20 Evercore ISI
Blackbaud upgraded to In Line from Underperform at Evercore ISI
04/20/20 Evercore ISI
Blackbaud upgraded to In Line from Underperform at Evercore ISI
ENTA Enanta
$52.23 /

+2.23 (+4.46%)

08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
MAXN Maxeon Solar
$19.11 /

-0.37 (-1.90%)

08/27/20 Goldman Sachs
Maxeon Solar initiated with a Neutral at Goldman Sachs
TRVN Trevena
$1.73 /

+0.165 (+10.54%)

K Kellogg
$69.49 /

-0.99 (-1.40%)

GIS General Mills
$63.71 /

-1 (-1.55%)

ENTA Enanta
$52.23 /

+2.23 (+4.46%)

BLKB Blackbaud
$66.07 /

+1.87 (+2.91%)

  • 12
    Aug
TRVN Trevena
$1.73 /

+0.165 (+10.54%)

K Kellogg
$69.49 /

-0.99 (-1.40%)

GIS General Mills
$63.71 /

-1 (-1.55%)

BLKB Blackbaud
$66.07 /

+1.87 (+2.91%)

TRVN Trevena
$1.73 /

+0.165 (+10.54%)

K Kellogg
$69.49 /

-0.99 (-1.40%)

GIS General Mills
$63.71 /

-1 (-1.55%)

BLKB Blackbaud
$66.07 /

+1.87 (+2.91%)

TRVN Trevena
$1.73 /

+0.165 (+10.54%)

GIS General Mills
$63.71 /

-1 (-1.55%)

Conference/Events
European Association for the Study of the Liver to hold a conference » 09:12
08/28/20
08/28
09:12
08/28/20
09:12
ABBV

AbbVie

$94.28 /

-0.04 (-0.04%)

, AKRO

Akero Therapeutics

$31.60 /

-2.06 (-6.12%)

, ALBO

Albireo Pharma

$27.44 /

-0.84 (-2.97%)

, AXLA

Axcella Health

$5.20 /

-0.13 (-2.44%)

, AZN

AstraZeneca

$56.11 /

-0.885 (-1.55%)

, BMY

Bristol-Myers

$62.52 /

+0.23 (+0.37%)

, CBAY

CymaBay

$6.14 /

-0.33 (-5.10%)

, DRRX

Durect

$1.89 /

-0.1 (-5.03%)

, ENTA

Enanta

$50.00 /

+0.2 (+0.40%)

, ETNB

89bio

$37.63 /

-0.63 (-1.65%)

, GILD

Gilead

$65.58 /

-0.01 (-0.02%)

, GLMD

Galmed

$5.06 /

-0.08 (-1.56%)

, VKTX

Viking Therapeutics

$7.44 /

-0.67 (-8.26%)

, VBIV

VBI Vaccines

$4.24 /

+1.035 (+32.29%)

, PLRX

Pliant Therapeutics

$24.36 /

-0.27 (-1.10%)

, PFE

Pfizer

$37.86 /

-0.21 (-0.55%)

, NVS

Novartis

$87.01 /

+0.01 (+0.01%)

, NVO

Novo Nordisk

$66.28 /

-0.475 (-0.71%)

, NGM

NGM Biopharmaceuticals

$17.85 /

-0.43 (-2.35%)

, MIRM

Mirum Pharmaceuticals

$23.60 /

-0.31 (-1.30%)

, MDGL

Madrigal Pharmaceuticals

$106.33 /

+1.03 (+0.98%)

, LMNL

Liminal BioSciences

$11.77 /

-0.5 (-4.07%)

, ICPT

Intercept

$48.72 /

+0.25 (+0.52%)

, GNFT

Genfit

$4.95 /

-0.07 (-1.39%)

Digital International…

Digital International Liver Congress 2020 will be held on August 27-29. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

LMNL Liminal BioSciences
$11.77 /

-0.5 (-4.07%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GNFT Genfit
$4.95 /

-0.07 (-1.39%)

GLMD Galmed
$5.06 /

-0.08 (-1.56%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

ENTA Enanta
$50.00 /

+0.2 (+0.40%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
08/20/20 Morgan Stanley
AbbVie price target raised to $108 from $95 at Morgan Stanley
08/19/20 Piper Sandler
AbbVie commercial efforts easier after Gilead CRL, says Piper Sandler
08/19/20 Stifel
Galapagos price target lowered to $155 from $187 at Stifel
AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

08/14/20 Piper Sandler
Piper sees 89bio's topline data beating Akero's in NASH
07/23/20 BTIG
89bio initiated with a Buy at BTIG
07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

08/19/20 H.C. Wainwright
Albireo Pharma price target lowered to $50 from $64 at H.C. Wainwright
07/30/20 Piper Sandler
Albireo Pharma initiated with an Overweight at Piper Sandler
07/16/20 H.C. Wainwright
Albireo price target raised to $64 at H.C. Wainwright after BOLD trial start
06/25/20
Fly Intel: Top five analyst initiations
AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

08/05/20 Piper Sandler
Axcella reported positive hepatic insufficiency data, says Piper Sandler
07/30/20 Piper Sandler
Axcella initiated with an Overweight at Piper Sandler
05/28/20
Fly Intel: Top five analyst initiations
05/28/20 Wedbush
Wedbush bullish on Axcella, initiates with an Outperform
AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
08/04/20 H.C. Wainwright
CymaBay price target raised to $13 from $9 at H.C. Wainwright
08/03/20 Cantor Fitzgerald
CymaBay price target raised to $20 from $15 at Cantor Fitzgerald
DRRX Durect
$1.89 /

-0.1 (-5.03%)

07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
07/01/20 H.C. Wainwright
Durect alcoholic hepatitis efficacy could be seen in COVID, says H.C. Wainwright
06/29/20 B. Riley Securities
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
ENTA Enanta
$50.00 /

+0.2 (+0.40%)

08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
ETNB 89bio
$37.63 /

-0.63 (-1.65%)

07/30/20 Piper Sandler
89bio initiated with an Overweight at Piper Sandler
07/23/20
Fly Intel: Top five analyst initiations
GILD Gilead
$65.58 /

-0.01 (-0.02%)

08/20/20 Truist
Gilead price target lowered to $67 from $74 at Truist
08/19/20 Piper Sandler
Piper Sandler trims Gilead target by $2, keeps Overweight rating
08/19/20 JPMorgan
Gilead CRL for filgotinib 'near worst case scenario,' says JPMorgan
GLMD Galmed
$5.06 /

-0.08 (-1.56%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley Securities
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley Securities
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

08/28/20 H.C. Wainwright
Viking Therapeutics price target raised to $21 from $18 at H.C. Wainwright
06/04/20 BMO Capital
Viking Therapeutics initiated with an Outperform at BMO Capital
05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley Securities
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
06/23/20 Oppenheimer
VBI Vaccines price target raised to $8 from $5 at Oppenheimer
PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

08/11/20 Piper Sandler
Pliant Therapeutics' approach to fibrotic diseases best in industry, says Piper
06/29/20 Needham
Pliant Therapeutics initiated with a Buy at Needham
06/29/20 Cowen
Pliant Therapeutics initiated with an Outperform at Cowen
06/29/20 Citi
Pliant Therapeutics initiated with a Buy at Citi
PFE Pfizer
$37.86 /

-0.21 (-0.55%)

08/27/20 Chardan
Moderna vaccine showed differentiation from BioNTech/Pfizer's, says Chardan
08/25/20 Truist
Forte Biosciences initiated with a Buy at Truist
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/21/20 Mizuho
Pfizer COVID vaccine data 'ok encouraging,' says Mizuho
NVS Novartis
$87.01 /

+0.01 (+0.01%)

08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
08/18/20 Raymond James
Teva could pay damages nearing $1B in DOJ FCA action, says Raymond James
08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

08/12/20 Piper Sandler
NGM Biopharmaceuticals' four pipeline programs underappreciated, says Piper
07/30/20 Piper Sandler
NGM Biopharmaceuticals initiated with an Overweight at Piper Sandler
07/07/20 Chardan
NGM Biopharmaceuticals initiated with a Buy at Chardan
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/03/20
Fly Intel: Top five analyst initiations
08/03/20 H.C. Wainwright
Mirum Pharmaceuticals initiated with a Buy at H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

07/30/20 Piper Sandler
Madrigal Pharmaceuticals initiated with an Overweight at Piper Sandler
06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley Securities
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
LMNL Liminal BioSciences
$11.77 /

-0.5 (-4.07%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

08/10/20 Stifel
Intercept price target raised to $56 from $51 at Stifel
08/10/20 Piper Sandler
Piper Sandler confident in success of Intercept's OCA approval in 2021
07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
GNFT Genfit
$4.95 /

-0.07 (-1.39%)

08/05/20 H.C. Wainwright
Lancet publication 'strong validation' Genfit's NIS4, says H.C. Wainwright
07/23/20 H.C. Wainwright
Genfit price target lowered to $8 from $11 at H.C. Wainwright
07/23/20
Fly Intel: Top five analyst upgrades
07/23/20 Stifel
Genfit upgraded to Buy from Hold at Stifel
VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

MIRM Mirum Pharmaceuticals
$23.60 /

-0.31 (-1.30%)

MDGL Madrigal Pharmaceuticals
$106.33 /

+1.03 (+0.98%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GLMD Galmed
$5.06 /

-0.08 (-1.56%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

ENTA Enanta
$50.00 /

+0.2 (+0.40%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AXLA Axcella Health
$5.20 /

-0.13 (-2.44%)

ALBO Albireo Pharma
$27.44 /

-0.84 (-2.97%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

  • 18
    Aug
  • 08
    Jul
  • 08
    Jul
  • 03
    Jun
  • 14
    May
  • 22
    Apr
  • 30
    Jan
  • 09
    Jan
  • 11
    Dec
  • 11
    Nov
  • 19
    Sep
VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

VKTX Viking Therapeutics
$7.44 /

-0.67 (-8.26%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PLRX Pliant Therapeutics
$24.36 /

-0.27 (-1.10%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

ICPT Intercept
$48.72 /

+0.25 (+0.52%)

GNFT Genfit
$4.95 /

-0.07 (-1.39%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

ETNB 89bio
$37.63 /

-0.63 (-1.65%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

AKRO Akero Therapeutics
$31.60 /

-2.06 (-6.12%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

VBIV VBI Vaccines
$4.24 /

+1.035 (+32.29%)

PFE Pfizer
$37.86 /

-0.21 (-0.55%)

NVS Novartis
$87.01 /

+0.01 (+0.01%)

NVO Novo Nordisk
$66.28 /

-0.475 (-0.71%)

NGM NGM Biopharmaceuticals
$17.85 /

-0.43 (-2.35%)

GILD Gilead
$65.58 /

-0.01 (-0.02%)

DRRX Durect
$1.89 /

-0.1 (-5.03%)

CBAY CymaBay
$6.14 /

-0.33 (-5.10%)

BMY Bristol-Myers
$62.52 /

+0.23 (+0.37%)

AZN AstraZeneca
$56.11 /

-0.885 (-1.55%)

ABBV AbbVie
$94.28 /

-0.04 (-0.04%)

Hot Stocks
Enanta to present data from hepatitis B virus, NASH programs at EASL » 06:17
08/28/20
08/28
06:17
08/28/20
06:17
ENTA

Enanta

$50.00 /

+0.2 (+0.40%)

Enanta Pharmaceuticals…

Enanta Pharmaceuticals announced that data from Enanta's wholly-owned development programs for non-alcoholic steatohepatitis and hepatitis B virus will be presented at the European Association for the Study of the Liver Digital International Liver Congress 2020. Data presented include results from the Phase 1a clinical trial of EDP-514, Enanta's core inhibitor for HBV. Additionally, Enanta's NASH program will be discussed in an oral presentation detailing the Phase 2a ARGON-1 study of EDP-305, Enanta's lead Farnesoid X receptor (FXR) agonist, and two posters highlighting preclinical data on EDP-297, Enanta's follow-on FXR agonist. "We are pleased to share scientific data across multiple candidates in our pipeline, supporting our chemistry-driven approach to developing innovative treatments for viral infections and liver diseases," stated Jay R. Luly, Ph.D., President and CEO of Enanta Pharmaceuticals. "The positive results from our first-in-human Phase 1a study of EDP-514, demonstrating a strong safety, tolerability and pharmacokinetic profile, gave us the confidence to advance our HBV program into two ongoing Phase 1b clinical studies in HBV patients. Additionally, the data presented for our NASH candidates further demonstrate the potential of both FXR agonists. EDP-305 shows statistically significant improvements in liver biochemistry and hepatic steatosis, and our follow-on NASH candidate EDP-297 demonstrates a potent anti-fibrotic effect."

ShowHide Related Items >><<
ENTA Enanta
$50.00 /

+0.2 (+0.40%)

ENTA Enanta
$50.00 /

+0.2 (+0.40%)

08/27/20 Roth Capital
Enanta resumed with a Buy at Roth Capital
08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
ENTA Enanta
$50.00 /

+0.2 (+0.40%)

Initiation
Enanta resumed with a Buy at Roth Capital » 16:19
08/27/20
08/27
16:19
08/27/20
16:19
ENTA

Enanta

$49.77 /

-0.03 (-0.06%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.

ShowHide Related Items >><<
ENTA Enanta
$49.77 /

-0.03 (-0.06%)

ENTA Enanta
$49.77 /

-0.03 (-0.06%)

08/25/20 Piper Sandler
Enanta initiated with an Overweight at Piper Sandler
07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
ENTA Enanta
$49.77 /

-0.03 (-0.06%)

Initiation
Enanta initiated with an Overweight at Piper Sandler » 16:09
08/25/20
08/25
16:09
08/25/20
16:09
ENTA

Enanta

$50.45 /

+1.49 (+3.04%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Enanta with an Overweight rating and $87 price target, which represents 77% potential upside. The company's "R&D expertise" is underappreciated and has not received enough credit for its three assets in clinical development, Rahimi tells investors in a research note

ShowHide Related Items >><<
ENTA Enanta
$50.45 /

+1.49 (+3.04%)

ENTA Enanta
$50.45 /

+1.49 (+3.04%)

07/27/20 JMP Securities
Enanta upgraded to Outperform from Market Perform at JMP Securities
03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
ENTA Enanta
$50.45 /

+1.49 (+3.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.